Nagging doesn’t help smokers quit

Nagging doesn’t help smokers quit

Advertising Material
Pfizer New Zealand
Pfizer Nagging
A visual of the TV awareness campaign that’s currently underway in New Zealand

Smoking cigarettes is a common health issue that may result in a person nagging their partner, friend or family member to quit

Evidence shows that nagging doesn’t work

A recent study showed that those with partners who offered emotional encouragement and practical support were more likely to stop smoking than those with unsupportive or nagging partners.1,2

The study by the University of Aberdeen and the University of Zurich tracked the behaviour of 100 couples with one smoker and one non-smoker.3

To address this, Pfizer has been raising awareness in New Zealand of the detrimental effect nagging can have on a person trying to quit.

Awareness campaign currently running in New Zealand on TV and YouTube

The campaign, which is aimed at raising awareness to smokers and their partners/spouses, features a couple in this scenario. Various conversations are played out that are likely to come up between many couples dealing with the issue.

These include the impact smoking has on how people look, spend money and even smell!

As well as running on national television, you can also access these clips on YouTube via the link below.

“It is upsetting to watch my partner slip back into his smoking habit again and again when he gets stressed. I start to nag him to quit smoking but he just gets frustrated and blocks me out”. - Penny, non-smoking partner of smoker

References
  1. Stadler, G. (2017). Personal Communication, University of Aberdeen
  2. University of Aberdeen (2017). Researchers Find Key To Stubbing Out Smoking. [online] Available at: https://www.abdn.ac.uk/news/8788/  Aberdeen University 12:23 PM 32 KB [Accessed 25 May 2017].
  3. König, C., Stadler, G., Knoll, N., Ochsner, S., Hornung, R. and Scholz, U. (2016). Invisible Support: Effects on the Provider's Positive and Negative Affect. Applied Psychology: Health and Well-Being, 8(2), pp.172-191
Mandatories

CHAMPIX® (varenicline tartrate) 0.5 mg and 1 mg tablets. 4.1 Therapeutic Indications: Aid to smoking cessation. 4.2 Dose and Method of Administration: Days 1-3: 0.5 mg once daily. Days 4-7: 0.5 mg twice daily. Day 8 - end of treatment: 1 mg twice daily. Patients should set a date to quit smoking and start dosing 1-2 weeks before this date. Alternatively, patients can start treatment and quit smoking between days 8 and 35 of treatment. Patients should be treated for 12 weeks. An additional 12 weeks of treatment can be considered for patients who have successfully stopped smoking at the end of 12 weeks. A gradual approach to quitting smoking should be considered for patients who are not willing/able to quit abruptly. Patients should reduce smoking during the first 12 weeks and quit by the end of that treatment period. Patients should then continue for an additional 12 weeks for a total of 24 weeks. Retreatment with varenicline is encouraged in patients who are motivated to quit and did not succeed with prior treatment or who relapsed. Dose tapering not required at end of treatment. Dose reduction is required for patients with severe renal impairment. Patients who cannot tolerate adverse effects may have the dose lowered temporarily or permanently. See Data Sheet for details. 4.3 Contraindications: Hypersensitivity to varenicline or excipients. 4.4 Special Warnings and Precautions for Use: history of, or, underlying psychiatric illness; neuropsychiatric symptoms including changes in behaviour or thinking, anxiety, psychosis, mood swings, agitation, aggression, depressed mood, suicidal ideation and suicidal behaviour; patients and families should be advised that the patient should stop taking CHAMPIX and contact a health care professional immediately if such symptoms are observed; patients and families should be alerted to the need to monitor for the possible emergence of neuropsychiatric symptoms; ongoing follow-up until resolution; seizures; hypersensitivity reactions; cardiovascular events; driving or operating machinery; alcohol consumption; pregnancy, lactation; severe renal impairment. See Data Sheet for details. 4.8 Undesirable Effects: Smoking cessation/nicotine withdrawal symptoms. Most common: nausea, headache, insomnia, nasopharyngitis, abnormal dreams, abdominal pain, dizziness, constipation, fatigue, diarrhoea, flatulence, vomiting, dyspepsia, dysgeusia, irritability, influenza, anxiety, dry mouth, sleep disorder, back pain, increased appetite, somnolence. Post-marketing reports of neuropsychiatric symptoms, myocardial infarction, stroke. See Data Sheet for details. 7. Medicine Schedule: Prescription Medicine; CHAMPIX is fully funded under Special Authority. Before prescribing please review Data Sheet available from MEDSAFE (www.medsafe.govt.nz) or Pfizer New Zealand Ltd (www.pfizer.co.nz) or call 0800 736 363. ®Registered trademark. V10417 © Pfizer 2018. Pfizer New Zealand Limited, Level 1, Suite 1.4, Building B, 8 Nugent Street, Grafton, Auckland 1023, PO Box 3998, Auckland, New Zealand. Toll Free 0800 736 363. essence PF8597 DA1742EB PP-CHM-NZL-0099 03/18.